These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24338022)

  • 1. Naturally occurring variants of the dysglycemic peptide pancreastatin: differential potencies for multiple cellular functions and structure-function correlation.
    Allu PK; Chirasani VR; Ghosh D; Mani A; Bera AK; Maji SK; Senapati S; Mullasari AS; Mahapatra NR
    J Biol Chem; 2014 Feb; 289(7):4455-69. PubMed ID: 24338022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Gly297Ser Variant of the Physiological Dysglycemic Peptide Pancreastatin Is a Novel Risk Factor for Cardiometabolic Disorders.
    Allu PKR; Kiranmayi M; Mukherjee SD; Chirasani VR; Garg R; Vishnuprabu D; Ravi S; Subramanian L; Sahu BS; Iyer DR; Maghajothi S; Sharma S; Ravi MS; Khullar M; Munirajan AK; Gayen JR; Senapati S; Mullasari AS; Mohan V; Radha V; Naga Prasad SV; Mahapatra NR
    Diabetes; 2022 Mar; 71(3):538-553. PubMed ID: 34862200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreastatin is an endogenous peptide that regulates glucose homeostasis.
    Valicherla GR; Hossain Z; Mahata SK; Gayen JR
    Physiol Genomics; 2013 Nov; 45(22):1060-71. PubMed ID: 24064537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism.
    O'Connor DT; Cadman PE; Smiley C; Salem RM; Rao F; Smith J; Funk SD; Mahata SK; Mahata M; Wen G; Taupenot L; Gonzalez-Yanes C; Harper KL; Henry RR; Sanchez-Margalet V
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5414-25. PubMed ID: 15956083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel target for the dysglycemic chromogranin A fragment pancreastatin: interaction with the chaperone GRP78 to influence metabolism.
    Biswas N; Friese RS; Gayen JR; Bandyopadhyay G; Mahata SK; O'Connor DT
    PLoS One; 2014; 9(1):e84132. PubMed ID: 24465394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional genetic variants of the catecholamine-release-inhibitory peptide catestatin in an Indian population: allele-specific effects on metabolic traits.
    Sahu BS; Obbineni JM; Sahu G; Allu PK; Subramanian L; Sonawane PJ; Singh PK; Sasi BK; Senapati S; Maji SK; Bera AK; Gomathi BS; Mullasari AS; Mahapatra NR
    J Biol Chem; 2012 Dec; 287(52):43840-52. PubMed ID: 23105094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated plasma levels of pancreastatin (PST) in patients with non-insulin-dependent diabetes mellitus (NIDDM).
    Funakoshi A; Tateishi K; Shinozaki H; Matsumoto M; Wakasugi H
    Regul Pept; 1990 Sep; 30(2):159-64. PubMed ID: 2274680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin.
    Sánchez-Margalet V; González-Yanes C; Najib S; Santos-Alvarez J
    Regul Pept; 2010 Apr; 161(1-3):8-14. PubMed ID: 20184923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreastatin inhibits insulin action in rat adipocytes.
    Sánchez-Margalet V; González-Yanes C
    Am J Physiol; 1998 Dec; 275(6):E1055-60. PubMed ID: 9843749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel pathway of insulin sensitivity in chromogranin A null mice: a crucial role for pancreastatin in glucose homeostasis.
    Gayen JR; Saberi M; Schenk S; Biswas N; Vaingankar SM; Cheung WW; Najjar SM; O'Connor DT; Bandyopadhyay G; Mahata SK
    J Biol Chem; 2009 Oct; 284(42):28498-509. PubMed ID: 19706599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreastatin, a chromogranin-A-derived peptide, inhibits insulin-stimulated glycogen synthesis by activating GSK-3 in rat adipocytes.
    González-Yanes C; Sánchez-Margalet V
    Biochem Biophys Res Commun; 2001 Nov; 289(1):282-7. PubMed ID: 11708813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance.
    Bandyopadhyay GK; Lu M; Avolio E; Siddiqui JA; Gayen JR; Wollam J; Vu CU; Chi NW; O'Connor DT; Mahata SK
    Diabetes; 2015 Jan; 64(1):104-16. PubMed ID: 25048197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunomodulatory functions of chromogranin A-derived peptide pancreastatin.
    Ioannidis M; Mahata SK; van den Bogaart G
    Peptides; 2022 Dec; 158():170893. PubMed ID: 36244579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-dependent effects of pancreastatin on insulin and glucagon release.
    von Schönfeld J; Kleimann J; Müller MK; Rünzi M; Goebell H
    Int J Pancreatol; 1991 Oct; 10(2):143-9. PubMed ID: 1748828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of pancreastatin inhibitor PSTi8 for the treatment of insulin resistance and diabetes: studies in rodent models of diabetes mellitus.
    Hossain Z; Valicherla GR; Gupta AP; Syed AA; Riyazuddin M; Chandra S; Siddiqi MI; Gayen JR
    Sci Rep; 2018 Jun; 8(1):8715. PubMed ID: 29880906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprint of: Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin.
    Sánchez-Margalet V; González-Yanes C; Najib S; Santos-Álvarez J
    Regul Pept; 2010 Nov; 165(1):71-7. PubMed ID: 20934461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the dysglycemic peptide, pancreastatin, using a human forearm model.
    Cadman PE; Rao F; Mahata SK; O'Connor DT
    Ann N Y Acad Sci; 2002 Oct; 971():528-9. PubMed ID: 12438174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galanin and pancreastatin inhibit stimulated insulin secretion in the mouse: comparison of effects.
    Lindskog S; Ahrén B
    Horm Res; 1988; 29(5-6):237-40. PubMed ID: 2464535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreastatin inhibitor PSTi8 attenuates hyperinsulinemia induced obesity and inflammation mediated insulin resistance via MAPK/NOX3-JNK pathway.
    Gupta AP; Syed AA; Garg R; Goand UK; Singh P; Riyazuddin M; Valicherla GR; Husain A; Gayen JR
    Eur J Pharmacol; 2019 Dec; 864():172723. PubMed ID: 31586632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A common genetic variant of the chromogranin A-derived peptide catestatin is associated with atherogenesis and hypertension in a Japanese population.
    Choi Y; Miura M; Nakata Y; Sugasawa T; Nissato S; Otsuki T; Sugawara J; Iemitsu M; Kawakami Y; Shimano H; Iijima Y; Tanaka K; Kuno S; Allu PK; Mahapatra NR; Maeda S; Takekoshi K
    Endocr J; 2015; 62(9):797-804. PubMed ID: 26211667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.